Related Experiment Video
Updated: Jan 3, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model
Sarah Tomkovich1, Nicholas A Lesniak1, Yuan Li1
1Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract:
Proton pump inhibitor (PPI) use has been associated with microbiota alterations and susceptibility to Clostridioides difficile infections (CDIs) in humans. We assessed how PPI treatment alters the fecal microbiota and whether treatment promotes CDIs in a mouse model. Mice receiving a PPI treatment were gavaged with 40 mg of omeprazole per kg of body weight during a 7-day pretreatment phase, the day of C. difficile challenge, and the following 9 days. We found that mice treated with omeprazole were not colonized by C. difficile When omeprazole treatment was combined with a single clindamycin treatment, one cage of mice remained resistant to C. difficile colonization, while the other cage was colonized. Treating mice with only clindamycin followed by challenge resulted in C. difficile colonization. 16S rRNA gene sequencing analysis revealed that omeprazole had minimal impact on the structure of the murine microbiota throughout the 16 days of omeprazole exposure. These results suggest that omeprazole treatment alone is not sufficient to disrupt microbiota resistance to C. difficile infection in mice that are normally resistant in the absence of antibiotic treatment.IMPORTANCE Antibiotics are the primary risk factor for Clostridioides difficile infections (CDIs), but other factors may also increase a person's risk. In epidemiological studies, proton pump inhibitor (PPI) use has been associated with CDI incidence and recurrence. PPIs have also been associated with alterations in the human intestinal microbiota in observational and interventional studies. We evaluated the effects of the PPI omeprazole on the structure of the murine intestinal microbiota and its ability to disrupt colonization resistance to C. difficile We found omeprazole treatment had minimal impact on the murine fecal microbiota and did not promote C. difficile colonization. Further studies are needed to determine whether other factors contribute to the association between PPIs and CDIs seen in humans or whether aspects of murine physiology may limit its utility to test these types of hypotheses.
Insights
Proton pump inhibitors (PPIs) like omeprazole did not increase Clostridioides difficile colonization in mice. Omeprazole alone did not disrupt gut microbiota resistance, suggesting other factors may influence PPI-associated CDI risk in humans.
Area of Science:
- Microbiology
- Gastroenterology
- Pharmacology
Background:
- Proton pump inhibitor (PPI) use is linked to increased risk of Clostridioides difficile infections (CDIs) in humans.
- PPIs may alter the gut microbiota, potentially reducing resistance to CDI.
- The exact mechanisms underlying the association between PPIs and CDI remain unclear.
Purpose of the Study:
- To investigate the impact of omeprazole, a PPI, on the murine fecal microbiota.
- To determine if omeprazole treatment alone or combined with clindamycin affects susceptibility to Clostridioides difficile colonization in mice.
Main Methods:
- Mice were treated with omeprazole (40 mg/kg) for 16 days, including a 7-day pretreatment.
- Some groups received concurrent or sequential clindamycin treatment.
- Fecal microbiota structure was analyzed using 16S rRNA gene sequencing.
Main Results:
- Omeprazole treatment alone did not lead to Clostridioides difficile colonization in mice.
- Combined omeprazole and clindamycin treatment showed variable resistance to colonization.
- Omeprazole exhibited minimal impact on the overall structure of the murine fecal microbiota.
Conclusions:
- Omeprazole monotherapy does not disrupt the gut microbiota's resistance to Clostridioides difficile in this mouse model.
- The findings suggest that factors beyond PPI-induced microbiota changes may contribute to the human association between PPIs and CDI.
- Further research is needed to elucidate the complex relationship between PPIs, microbiota, and CDI.
More Related Videos
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

